Breaking the barrier - An integrated multidisciplinary approach to kill Gram-negative bacteria through existing antibiotics by making their outer membrane permeable

Projektinformationen

BREAKthrough

ID Finanzhilfevereinbarung: 101072632

DOI

10.3030/101072632

EK-Unterschriftsdatum 14 Juli 2022

Startdatum 1 Januar 2023

Enddatum 30 September 2027

Finanziert unter

• Marie Skłodowska-Curie Actions (MSCA)

Gesamtkosten

Keine Daten

EU-Beitrag

€ 2 618 488,80

Koordiniert durch

UNIVERSITE CATHOLIQUE DE LOUVAIN
Belgium

Periodic Reporting for period 1 - BREAKthrough (Breaking the barrier - An integrated multidisciplinary approach to kill Gram-negative bacteria through existing antibiotics by making their outer membrane permeable)

Berichtszeitraum: 2023-01-01 bis 2024-12-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Antimicrobial resistance (AMR) represents one of the most urgent public health crises worldwide, severely undermining our ability to treat bacterial infections and leading to significant mortality, morbidity, and economic burden. Gram-negative bacteria pose a particular threat due to their complex outer membrane structure, which severely restricts antibiotic entry and facilitates resistance. The BREAKthrough project addresses this critical challenge by targeting key processes involved in Gram-negative bacterial envelope biogenesis. The overarching objective of BREAKthrough is to identify and exploit novel druggable interactions within these essential bacterial envelope machineries to develop innovative antibacterial compounds capable of permeabilizing the outer membrane. To achieve this, the project integrates multidisciplinary approaches spanning structural biology, chemistry, microbiology, advanced screening technologies, and in vivo infection models. By combining these approaches, BREAKthrough aims to uncover previously unexplored vulnerabilities in Gram-negative bacteria, thereby paving the way for the discovery of novel therapeutic agents; BREAKthrough will significantly enhance our understanding of bacterial envelope biology and antibiotic permeability mechanisms. The development of novel antibacterial compounds will contribute addressing the urgent market need for effective therapies against multidrug-resistant pathogens. Thus, the project is positioned to deliver meaningful solutions in the global fight against antimicrobial resistance.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

During the first reporting period, the BREAKthrough project successfully carried out a range of technical and scientific activities, including the biochemical and structural characterization of major bacterial envelope machineries. Also, significant advances were achieved in elucidating druggable interactions.
Additionally, robust screening methodologies were developed and optimized, including target-based and stress-based assays, as well as innovative in vivo models. These assays facilitated the identification and evaluation of novel synthetic and natural compounds, demonstrating potential to compromise bacterial outer membrane integrity. Chemical synthesis activities led to the generation of novel small-molecule libraries targeting envelope assembly machineries.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

The results have strong potential impacts by significantly advancing antibacterial therapies targeting Gram-negative bacterial infections, addressing critical global health challenges related to antimicrobial resistance. To ensure further uptake and success, additional research, preclinical validation, comprehensive IP strategies, and supportive regulatory frameworks will be crucial.

The BREAKthrough DCs at the second annual meeting in Bled, Slowenia